Clinical safety and tolerability of losartan

Clinical Therapeutics

Volumn 19, Issue 4, 1997, Pages 604-616

  Weber, Michael ^a  

^a BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

Angiotensin II receptor blocker; Congestive heart failure; Hypertension; Losartan; Renal dysfunction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIHYPERTENSIVE AGENT; LOSARTAN; PLACEBO;

ARTICLE; ASTHENIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ESSENTIAL HYPERTENSION; FATIGUE; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0030798211     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80086-0     Document Type: Article

References (15)

1. Lindpainter K, Ganten D. The cardiac renin-angiotensin system: An appraisal of present experimental and clinical evidence. Circ Res. 1991;68:905-921.
2. Daemen MJAP, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res. 1991;68:450-456.
3. Lee RJ. Nonpeptide angiotensin II receptor antagonists. Introduction. Am J Hypertens. 1991;4(Suppl 4):271S-272S.
4. Madhun ZT, Ernsberger P, Ke F-C, et al. Signal transduction mediated by angiotensin II receptor subtypes expressed in rat renal mesangial cells. Regul Pept. 1993;44:149-157.
5. Pals DT, Denning GS Jr, Keenen RE. Historical development of saralasin. Kidney Int. 1979;15(Suppl 19):7-10.
6. Timmermans PBMWM, Chiu AT, Herblin WF, et al. Angiotensin II receptor subtypes. Am J Hypertens. 1992;5:406-410.
7. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther. 1995; 17:911-923.
8. Dahlof B, Keller SE, Makris L, et al. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension. Am J Hypertens. 1995;8:578-583.
9. Chan JCN, Critchlery JAJH, Lappe JT, et al. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension. J Hum Hypertens. 1995;9:765-771.
10. Weir MR, Elkins M, Liss C, et al. Efficacy, tolerability and quality of life of losartan alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther. 1996; 18:411-428.
11. Oparil S, Barr E, Elkins M, et al. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension. Clin Ther. 1996;18: 608-625.
12. Lo M-W, Goldberg MR, McCrea JB, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther. 1995;58:641-649.
13. Nelson EB, Harn SC, Goldberg M, et al. Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonists. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York, NY: Raven Press; 1995:2895-2916.
14. Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension. 1995;26:112-117.
15. Data on file, Merck & Co., Inc., 1993.